Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is ...

Nxera Pharma has reported encouraging top-line data from a phase 3 clinical trial of its insomnia treatment daridorexant in ...

Insomnia Supplements Market is projected to reach USD 17.3 Bn by 2036, driven by rising sleep disorders, growing demand for ...

New research presented at Sleep 2025 highlights a growing insomnia crisis among caregivers, with women bearing the ...

Used in healing practices for centuries, modern versions of these spiky mats are increasingly popular, and many people find them invaluable. Here’s what the science says ...

Elevate your leadership impact with Journal of Nursing Leadership (JNL) – the premier subscription for nursing and midwifery ...

Middle-aged adults with comorbid insomnia and sleep apnea faced significantly elevated odds for uncontrolled hypertension vs. adults without these conditions, according to results published in Annals ...

Nxera Pharma, which has facilities in Cambridge UK, reports positive results from a Phase 3 trial of potential insomnia solution Daridorexant in South Korea.

Approved as Quviviq in Japan, daridorexant is being marketed through a partnership between Nxera and Shionogi.

People struggling with insomnia tend to hyperfocus on the fact that they can't sleep, which can prevent them from getting any shut-eye. Experts share effective practices to overcome sleep stress.

About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and irritability as well as increased health risks like diabetes and heart risks if ...

People struggling with insomnia tend to hyperfocus on the fact that they can't sleep, which can prevent them from getting any ...